[go: up one dir, main page]

MX2017001985A - Composiciones para inhibir la inflamacion en un sujeto con lesion de medula espinal y metodos de uso de las mismas. - Google Patents

Composiciones para inhibir la inflamacion en un sujeto con lesion de medula espinal y metodos de uso de las mismas.

Info

Publication number
MX2017001985A
MX2017001985A MX2017001985A MX2017001985A MX2017001985A MX 2017001985 A MX2017001985 A MX 2017001985A MX 2017001985 A MX2017001985 A MX 2017001985A MX 2017001985 A MX2017001985 A MX 2017001985A MX 2017001985 A MX2017001985 A MX 2017001985A
Authority
MX
Mexico
Prior art keywords
compositions
subject
spinal cord
cord injury
methods
Prior art date
Application number
MX2017001985A
Other languages
English (en)
Inventor
M Criscione Jason
m reynolds Francis
DAI Haining
A Bader Rebecca
Original Assignee
Pixarbio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pixarbio Corp filed Critical Pixarbio Corp
Publication of MX2017001985A publication Critical patent/MX2017001985A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)

Abstract

Se proporcionan en la presente composiciones para inhibir la inflamación en un sujeto con lesión de médula espinal que comprenden uno o más agentes capaces de reducir específicamente la señalización de TNF-a y un portador biodegradable. Se proporcionan además en la presente composiciones para inhibir la inflamación en un sujeto con lesión de médula espinal que comprenden uno o más agentes capaces de modular la señalización de MCP-1 y un portador biodegradable. También se describen métodos para tratar la inflamación en un sujeto que tiene una lesión de la médula espinal y equipos para producir las composiciones.
MX2017001985A 2014-08-15 2015-08-14 Composiciones para inhibir la inflamacion en un sujeto con lesion de medula espinal y metodos de uso de las mismas. MX2017001985A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462037628P 2014-08-15 2014-08-15
PCT/US2015/045199 WO2016025789A1 (en) 2014-08-15 2015-08-14 Compositions for inhibting inflammation in a subject with a spinal cord injury and methods of using the same

Publications (1)

Publication Number Publication Date
MX2017001985A true MX2017001985A (es) 2017-09-13

Family

ID=55301305

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001985A MX2017001985A (es) 2014-08-15 2015-08-14 Composiciones para inhibir la inflamacion en un sujeto con lesion de medula espinal y metodos de uso de las mismas.

Country Status (11)

Country Link
US (1) US20160045439A1 (es)
EP (1) EP3180026A4 (es)
JP (1) JP2017527611A (es)
CN (1) CN107073112A (es)
AU (1) AU2015301530A1 (es)
BR (1) BR112017002980A2 (es)
CA (1) CA2958195A1 (es)
EA (1) EA201790391A1 (es)
IL (1) IL250523A0 (es)
MX (1) MX2017001985A (es)
WO (1) WO2016025789A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107924999B (zh) * 2015-07-22 2022-04-19 默克专利有限公司 用于有机电致发光器件的材料
US20170239183A1 (en) * 2016-02-23 2017-08-24 PixarBio Corporation COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME
CN106491614A (zh) * 2016-12-06 2017-03-15 郑州郑先医药科技有限公司 一种用于治疗脊髓损伤的西药组合及用途
US20220411398A1 (en) * 2019-06-24 2022-12-29 University Of Iowa Research Foundation Jnk inhibitors as anticancer agents
CN111773216A (zh) * 2020-07-29 2020-10-16 陈洪亮 C-jun n末端激酶抑制剂su3327的用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
CA2317090A1 (en) * 1997-12-30 1999-07-08 Jari Koistinaho Tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases of nervous system
SE9803710L (sv) * 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US7906481B2 (en) * 1998-09-25 2011-03-15 Sciaticon Ab Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
US6537549B2 (en) * 1999-02-24 2003-03-25 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds
CA2480082A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
CA2497804A1 (en) * 2002-09-12 2004-03-25 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-human mcp-1 antibody and fragment of said antibody
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
NZ554426A (en) * 2004-10-01 2010-05-28 Ramscor Inc Conveniently implantable sustained release drug compositions comprising at least one non-polymeric excipient
US8535640B1 (en) * 2005-01-04 2013-09-17 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
KR20130056348A (ko) * 2008-09-25 2013-05-29 인비보 테라퓨틱스 코포레이션 척수 외상, 염증, 및 면역 질환: 치료제의 국소적 제어 방출
TWI434833B (zh) * 2009-06-03 2014-04-21 Intermune Inc 用於合成吡非尼酮（ｐｉｒｆｅｎｉｄｏｎｅ）的改良方法
KR101091028B1 (ko) * 2009-07-02 2011-12-09 아주대학교산학협력단 체내 주입형 하이드로젤 및 이의 생의학적 용도
US20150111899A1 (en) * 2009-12-04 2015-04-23 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome p450
US9060978B2 (en) * 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
CN103491950A (zh) * 2011-02-24 2014-01-01 普渡研究基金会 用于早期神经修复的纳米药物
US9962428B2 (en) * 2012-12-21 2018-05-08 National University Corporation Nagoya University Composition having tissue-repairing activity, and use therefor

Also Published As

Publication number Publication date
JP2017527611A (ja) 2017-09-21
IL250523A0 (en) 2017-03-30
CN107073112A (zh) 2017-08-18
BR112017002980A2 (pt) 2017-12-12
EP3180026A4 (en) 2018-04-11
CA2958195A1 (en) 2016-02-18
WO2016025789A8 (en) 2016-03-17
US20160045439A1 (en) 2016-02-18
EP3180026A1 (en) 2017-06-21
WO2016025789A1 (en) 2016-02-18
AU2015301530A1 (en) 2017-03-02
EA201790391A1 (ru) 2017-06-30

Similar Documents

Publication Publication Date Title
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CL2016002849A1 (es) Oligómeros y conjugados de oligómeros
CL2018000429A1 (es) Moduladores de la expresión de kras
CR20150316A (es) Compuestos y sus métodos de empleo
CL2017001464A1 (es) Modulación inmunológica
EP3696831A4 (en) PLANAR TRANSFORMER, POWER SOURCE SWITCHING CIRCUIT AND ADAPTER
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
CR20150457A (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
AU362319S (en) Pet treat
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
MX2017005555A (es) Inhibidores del bromodominio.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
BR112015023026A2 (pt) indicador de esterilização para esterilizantes oxidativos e processo para determinar a eficácia de um processo de esterilização utilizando esterilizantes oxidativos
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
BR112016019510A2 (pt) esterilização e filtração de composições de peptídeos
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX2017001985A (es) Composiciones para inhibir la inflamacion en un sujeto con lesion de medula espinal y metodos de uso de las mismas.
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2017012553A (es) Compuestos espirociclicos.
BR112017008097A2 (pt) método para tratar condições oculares
MX2015013378A (es) Uso de sedoheptulosa para la prevencion y tratamiento de inflamacion.
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
MX2017007492A (es) Prevención y tratamiento de condiciones inflamatorias.